Fluorescent in Situ Hybridization (FISH) Market By Emerging Trends, Business Strategies, Technologies,and Opportunities

PRESS RELEASE
Published November 8, 2023

Data Bridge Market Research analyzes that the Global Fluorescent in Situ Hybridization (FISH) Market is expected to grow at a CAGR of 8.2% in the forecast period of 2023 to 2030 and is expected to reach USD 1,830.55 million by 2030. The consumables segment is projected to propel the market growth as they are widely used in the FISH technology for the diagnosis of genetic disorders in various regions and more due to the availability of more advanced technologies. Especially, these consumables have a broad range of applications for research and clinical purposes among others.

Data Bridge Market Research analyzes that the global Fluorescent in Situ Hybridization (FISH) market is expected to reach a value of USD 1,830.55 million by 2030, at a CAGR of 8.2% during the forecast period. The product type segment accounts for the largest segment in the market due to the rising number of breast cancer and genetic disorders among patients. This market report also covers pricing analysis, patent analysis, and technological advancements in depth.

Request a Sample PDF:  https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-fluorescent-in-situ-hybridization-fish-market&Shri

Growing Burden of Genetic Disorders as well as Cancer

Genetic abnormalities are uncommon as a whole but are very frequent as individual ailments. Gene changes are the cause of all cancer. Just 5% to 10% of cancers are genetically predisposed. Nevertheless, when the same cancer types run in families, heredity may occasionally seem to be the cause of cancer. Hematologic and solid cancers are both heterogeneous diseases with various genetic abnormalities. An increasing number of genomic abnormalities, such as gain, loss, or rearrangement of chromosomal fragments and gene mutations, have been found to be driving factors in the pathogenesis of various malignancies as a result of the extensive investigations into the relationship between genomic instability and disease pathogenesis conducted over the last two decades. The clinical diagnosis of different chromosomal abnormalities, including deletions, duplications, and translocations, depends on FISH and other in situ hybridization techniques.

Market Definition

A molecular cytogenetic technique called Fluorescence in Situ Hybridization (FISH) enables the localization of a particular DNA sequence or an entire chromosome in a cell. It is used to diagnose genetic disorders, map genes, identify chromosomal anomalies, and may also be used to compare how the genes on different chromosomes in related species are organized. While performing FISH, the double helix structure is unwound and all probes connected to fluorescent molecules are bound to a particular sequence of sample DNA that can be seen under a fluorescence microscope.

FISH is frequently used for diagnostic purposes in oncology, preventative and reproductive health, and genomic and cell biology research. It is the industry-recognized method for finding infectious illnesses and chromosomal abnormalities. However, strict regulations and standards for the approval of FISH products and probes are expected to restrain the market growth.

Opportunity

  • Rising Public Awareness about the Early Detection of Genetic Abnormalities

Genetic testing aids patients in making important decisions in the prevention, treatment, or early detection of hereditary disorders. Low awareness of the importance of genetic testing contributes to the increase in the incidence of hereditary disorders.

A genetic disorder is a health condition that is inherited by a person, usually caused by mutations in the DNA or changes in the number or overall structure of chromosomes. Several types of commonly known diseases have been determined to be related to hereditary gene mutations.

Henceforth, the rising awareness about the early detection of genetic disorders using the FISH technique helps in the diagnosis of genetic diseases, gene mapping, and identification of novel oncogenes or genetic aberrations contributing to various types of cancers and genetic disorders, which provides the opportunity for market growth.

Recent Developments

  • In March 2023, Abcam plc. announced that it has received “Antibody Supplier of the Year”  in CiteAb’s distinguished annual industry awards. This comes after Fast Company recently listed Abcam plc. as one of the most innovative companies in the world for its ground-breaking efforts to increase data reproducibility. The provider with the most antibody product citations in 2022 receives CiteAb’s “Antibody Supplier of the Year” honor. Moreover, Abcam plc. was given a “highly commended” rating in the category of “Post Translational Modification Antibody Supplier of the Year,” recognizing the difficulty in creating and validating antibodies for these challenging targets. This has aided the business in becoming known on a global scale
  • In March 2023, BIOZOL Diagnostics Vertrieb GmbH announced the acquisition of AlphaScience GmbH. By making this acquisition, BIOZOL Diagnostics Vertrieb GmbH strengthened its dominant position in the global market for research and diagnostics. With a significant number of new supplier connections, outstanding product knowledge, and staff who are well-trained technically, AlphaScience enhances BIOZOL. Significant synergy effects between the two organizations improving their offerings to customers and suppliers
  • In July 2022, Bio-Techne announced the launch of the CE-IVD designated RNAscope ISH Probe High Risk HPV in Europe in order to help patients with Oropharyngeal Squamous Cell Carcinoma (OPSCC) identify high-risk Human Papillomavirus (HPV). For the qualitative identification of HPV E6/E7 mRNA in FFPE tissue samples, the RNAscope ISH Probe High Risk HPV is used. This has aided the business in offering better solutions all over the world

Browse Complete Report Details- https://www.databridgemarketresearch.com/reports/global-fluorescent-in-situ-hybridization-fish-market?Shri

Some of the major market players operating in the global Fluorescent in Situ Hybridization (FISH) market are Thermo Fisher Scientific Inc., Bio-Techne, Abbott, Agilent Technologies, Inc., Merck KGaA, F. Hoffmann-La Roche Ltd, Abnova Corporation, BioDot, Biocare Medical, LLC, Abcam plc., Sysmex Asia Pacific Pte Ltd (a subsidiary of Sysmex Corporation), BIOZOL Diagnostics Vertrieb GmbH, Zytomed Systems GmbH, Genemed Biotechnologies, Inc., Bio SB, BioGenex, Excilone, MetaSystems, Kaneka Eurogentec S.A., BioCat GmbH, and Leica Biosystems Nussloch GmbH among others.

 Fluorescent in Situ Hybridization (FISH) Market Scope

BY PRODUCT TYPE

  • CONSUMABLES
  • INSTRUMENT
  • SOFTWARE

Based on product type, the market is segmented into consumables, instrument, and software.

BY TECHNOLOGY

  • DNA FLUORESCENT IN SITU HYBRIDIZATION
  • RNA FLUORESCENT IN SITU HYBRIDIZATION
  • PNA FLUORESCENT IN SITU HYBRIDIZATION
  • OTHERS

Based on technology, the market is segmented into DNA fluorescent in situ hybridization, RNA fluorescent in situ hybridization, PNA fluorescent in situ hybridization, and others.

BY APPLICATION

  • CANCER RESEARCH
  • GENETIC RESEARCH
  • INFECTIOUS DISEASE
  • PERSONALIZED MEDICINE
  • OTHER

Based on application, the market is segmented into cancer research, genetic research, infectious disease, personalized medicine, and other.

BY USAGE

  • CLINICAL
  • RESEARCH
  • COMPANION DIAGNOSTIC

Based on usage, the market is segmented into clinical, research, and companion diagnostic.

BY END USER

  • HOSPITALS & CLINICS
  • DIAGNOSTIC LABORATORIES
  • PHARMACEUTICALS & BIOTECHNOLOGY COMPANIES
  • CONTRACT RESEARCH ORGANISATIONS
  • ACADEMIC & RESEARCH ORGANISATIONS
  • OTHERS

Based on end user, the market is segmented into hospitals & clinics, diagnostic laboratories, pharmaceuticals & biotechnology companies, contract research organizations, academic & research institutes, and others.

BY DISTRIBUTION CHANNEL

  • RETAIL SALES
  • DIRECT TENDER
  • ONLINE SALES
  • OTHERS

Drivers

  • Growing Burden of Genetic Disorders as Well as Cancer

Genetic abnormalities are uncommon as a whole but are very frequent as individual ailments. Gene changes are the cause of all cancer. Just 5% to 10% of cancers are genetically predisposed. Nevertheless, when the same cancer types run in families, heredity may occasionally seem to be the cause of cancer. Hematologic and solid cancers are both heterogeneous diseases with various genetic abnormalities. An increasing number of genomic abnormalities such as gain, loss, or rearrangement of chromosomal fragments and gene mutations, are driving factors in the pathogenesis of various malignancies as a result of the extensive investigations into the relationship between genomic instability and disease pathogenesis conducted over the last two decades. The clinical diagnosis of different chromosomal abnormalities, including deletions, duplications, and translocations, depends on FISH and other in situ hybridization techniques, which drives market growth.

Key Advantages of the Report: 

  • This study provides an analytical overview of the industry, including current trends and future predictions to identify potential investment opportunities.
  • The report offers insights into key drivers, limitations, and prospects, along with a comprehensive market share analysis.
  • The report quantitatively assesses the current market, shedding light on its growth prospects.
  • A Porter’s five forces analysis gauges the bargaining power of buyers and suppliers in the market.
  • The report delivers an in-depth market analysis that considers competitive dynamics and forecasts the future competitive landscape.

What to Anticipate from the Report – A 7-Point Guide:

  • The report delves into the holistic strategy and innovation within the market ecosystem.
  • It highlights prominent market drivers and obstacles, providing clarity on technological standardization and regulatory frameworks.
  • The report evaluates various implementation models and examines numerous use cases.
  • Serving as a valuable resource, the report offers essential industry insights, showcasing information on new investments, stakeholders, relevant contributors, and market participants.
  • Through the forecast period, the report conducts a thorough market analysis, referencing historical developments, ongoing events, and future growth prospects.

Top DBMR Healthcare Reports:         

Global Throat Cancer Diagnostics Market              https://www.databridgemarketresearch.com/reports/global-throat-cancer-diagnostics-market

Europe Throat Cancer Diagnostics Market              https://www.databridgemarketresearch.com/reports/europe-throat-cancer-diagnostics-market

Asia-Pacific Throat Cancer Diagnostics Market              https://www.databridgemarketresearch.com/reports/asia-pacific-throat-cancer-diagnostics-market

Middle East and Africa Throat Cancer Diagnostics Market              https://www.databridgemarketresearch.com/reports/middle-east-and-africa-throat-cancer-diagnostics-market

North America Throat Cancer Diagnostics Market              https://www.databridgemarketresearch.com/reports/north-america-throat-cancer-diagnostics-market

Global Hip Replacement Implants Market              https://www.databridgemarketresearch.com/reports/global-hip-replacement-implants-market

Swiss Hip Replacement Implants Market              https://www.databridgemarketresearch.com/reports/swiss-hip-replacement-implants-market

Global Polymerase Chain Reaction Market              https://www.databridgemarketresearch.com/reports/global-polymerase-chain-reaction-market

U.S. Polymerase Chain Reaction Market              https://www.databridgemarketresearch.com/reports/us-polymerase-chain-reaction-market

U.S. Bioabsorbable Orthopedics Implants Market              https://www.databridgemarketresearch.com/reports/us-bioabsorbable-orthopedics-implants-market

U.A.E Aesthetics/Cosmetics Market              https://www.databridgemarketresearch.com/reports/uae-aesthetics-cosmetics-market

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475

Email:- corporatesales@databridgemarketresearch.com

CDN Newswire